Skip Standard Navigation Links
Centers for Disease Control and Prevention
 CDC Home Search Health Topics A-Z
peer-reviewed.gif (582 bytes)
eid_header.gif (2942 bytes)
Past Issue

Vol. 11, No. 6
June 2005

EID Home | Ahead of Print | Past Issues | EID Search | Contact Us | Announcements | Suggested Citation | Submit Manuscript

Comments Comments



Back to article

Dispatch

Macrolide- and Telithromycin-resistant Streptococcus pyogenes, Belgium, 1999–2003

Surbhi Malhotra-Kumar,*Comments Christine Lammens,* Sabine Chapelle,* Monique Wijdooghe,* Jasper Piessens,* Koen Van Herck,* and Herman Goossens*
*University of Antwerp, Antwerp, Belgium



Appendix Table 1. In vitro activity of 6 antimicrobial agents against macrolide-resistant Streptococcus pyogenes phenotypes during 1999–2003


Antimicrobial*

Constitutive (n = 209)

M (n = 279)

Inducible (n = 18)




Range

MIC50

MIC90

Range

MIC50

MIC90

Range

MIC50

MIC90


Erythromycin

4–>512

>512

>512

1–128

8

16

1–>512

4

>512

Clindamycin

2–>512

>512

>512

≤0.03–4

0.06

1

0.125–256

0.75

128

Clarithromycin

1–>512

>512

>512

1–256

8

16

0.5–>512

2

>512

Azithromycin

4–>512

>512

>512

1–128

8

16

0.5–>512

4

>512

Tetracycline

0.06–128

32

64

≤0.03–64

0.25

0.5

0.06–64

0.5

64

Telithromycin†

0.0075–32

1

8

0.0075–2

0.5

0.5

0.003–4

0.06

0.5


*Dilution range of 0.03 to 512 μg/mL for all antimicrobial agents except telithromycin, which is 0.00375 to 64 μg/mL.

†Breakpoints for telithromycin, susceptible ≤1μg/mL, resistant ≥4 μg/mL.

   
     
   
Comments to the Authors

Please use the form below to submit correspondence to the authors or contact them at the following address:

Surbhi Malhotra-Kumar, Department of Medical Microbiology, Campus Drie Eiken, University of Antwerp, S3, Universiteitsplein 1, B-2610 Wilrijk, Antwerp, Belgium; fax: 32-3-820-26-63; email: surbhi.malhotra@ua.ac.be

Please note: To prevent email errors, please use no web addresses, email addresses, HTML code, or the characters <, >, and @ in the body of your message.

Return email address optional:


 


Comments to the EID Editors
Please contact the EID Editors at eideditor@cdc.gov

 

EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z

This page posted May 10, 2005
This page last reviewed May 11, 2005

Emerging Infectious Diseases Journal
National Center for Infectious Diseases
Centers for Disease Control and Prevention